ShangPharma considers going private amid compliance costs, share weakness
This article was originally published in Scrip
The costs of compliance with disclosure and financial reporting obligations for public firms in the US, and a share price well below the initial public offering level, have apparently prompted another mid-sized Chinese operation in the pharma space to consider delisting.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
Join us for a brief audio roundup of the major developments in the international biopharma industry over the past week, as covered by Scrip's global team.